DE69635130D1 - Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge - Google Patents

Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge

Info

Publication number
DE69635130D1
DE69635130D1 DE69635130T DE69635130T DE69635130D1 DE 69635130 D1 DE69635130 D1 DE 69635130D1 DE 69635130 T DE69635130 T DE 69635130T DE 69635130 T DE69635130 T DE 69635130T DE 69635130 D1 DE69635130 D1 DE 69635130D1
Authority
DE
Germany
Prior art keywords
reduce
weight loss
complications
fatty acid
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69635130T
Other languages
English (en)
Other versions
DE69635130T2 (de
Inventor
P Kuhajda
R Pasternack
A Townsend
S Mani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69635130D1 publication Critical patent/DE69635130D1/de
Publication of DE69635130T2 publication Critical patent/DE69635130T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69635130T 1995-11-17 1996-11-15 Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge Expired - Fee Related DE69635130T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US694095P 1995-11-17 1995-11-17
PCT/US1996/017678 WO1997018806A1 (en) 1995-11-17 1996-11-15 Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Publications (2)

Publication Number Publication Date
DE69635130D1 true DE69635130D1 (de) 2005-10-06
DE69635130T2 DE69635130T2 (de) 2006-06-14

Family

ID=21723376

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635130T Expired - Fee Related DE69635130T2 (de) 1995-11-17 1996-11-15 Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge

Country Status (7)

Country Link
EP (1) EP0869784B1 (de)
AT (1) ATE303144T1 (de)
AU (1) AU7668596A (de)
DE (1) DE69635130T2 (de)
DK (1) DK0869784T3 (de)
ES (1) ES2251002T3 (de)
WO (1) WO1997018806A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
CA2450660C (en) 2001-06-13 2011-08-16 Magnachem International Laboratories, Inc. Lactone formulations and method of use
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
BRPI0312413A2 (pt) * 2002-07-01 2016-08-02 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
JP5616220B2 (ja) 2007-06-01 2014-10-29 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
CN102265154A (zh) 2008-10-24 2011-11-30 马格纳化学国际实验室公司 用于筛选与rad9选择性相互作用的化合物的方法
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
AU2014249003A1 (en) 2013-03-13 2015-10-15 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of FASN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028397A (en) * 1973-07-05 1977-06-07 Hoffmann-La Roche Inc. Hydroxycitric acid derivatives
US4218443A (en) * 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
JP2746372B2 (ja) * 1988-03-11 1998-05-06 科研製薬株式会社 Ｆ−０３６８物質
GB9209628D0 (en) * 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
MX9304501A (es) * 1992-07-24 1994-04-29 Univ Johns Hopkins Quimioterapia para cancer.

Also Published As

Publication number Publication date
DK0869784T3 (da) 2006-01-16
EP0869784A4 (de) 2001-02-07
EP0869784B1 (de) 2005-08-31
WO1997018806A1 (en) 1997-05-29
AU7668596A (en) 1997-06-11
ATE303144T1 (de) 2005-09-15
DE69635130T2 (de) 2006-06-14
ES2251002T3 (es) 2006-04-16
EP0869784A1 (de) 1998-10-14

Similar Documents

Publication Publication Date Title
Morrow et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation.
Sugimura Studies on environmental chemical carcinogenesis in Japan
Reiterer et al. Zinc deficiency increases plasma lipids and atherosclerotic markers in LDL-receptor–deficient mice
Arbogast et al. Bowman-Birk inhibitor concentrate prevents atrophy, weakness, and oxidative stress in soleus muscle of hindlimb-unloaded mice
Haynes Physiologically active unsatured lactones
DE69635130T2 (de) Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
Shih et al. Concentration-dependent differential effects of quercetin on rat aortic smooth muscle cells
Cherian Effect of papaya latex extract on gravid and non-gravid rat uterine preparations in vitro
AU690853B2 (en) Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient
JP2004519455A (ja) 脂質および／または骨密度の調節ならびにそのための組成物
MXPA02012038A (es) Analogos heterociclicos novedosos de compuestos de difeniletileno.
Auyong et al. Pharmacological aspects of juglone
TW200513194A (en) Fat and oil processed composition for prevention and/or amelioration of life-style related disease
Böhm et al. Excessive reversible phenobarbital induced nuclear DNA-polyploidization in the growing mouse liver
Turner Garlic and circulatory disorders
Aellig et al. Is the ISA of pindolol beta 2‐adrenoceptor selective?
Kawano et al. Strain differences in butylated hydroxytoluene-induced deaths in male mice
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
Fabricio Main resveratrol action mechanisms in postmenopausal osteoporosis
Ranjha A Critical Review on Alpha Tocopherol: Sources
DE69805445D1 (de) Matthiolasamen öl, dieses enthaltende zusammensetzungen und deren verwendung
NAGATA et al. Effect of ascorbic acid 2-O-α-glucoside on hydrocortisone-induced cataract formation in developing chick embryos: II. Influence on glutathione and lipid peroxide contents in the lens
JPH05192092A (ja) アミラーゼ阻害物質を配合してなるペットフード
Su et al. Role of inflammation in skeletal muscle, connective tissue, and exertional injuries: to block or not to block?: NSAID therapy effects on healing of bone, tendon, and the enthesis
RU2127113C1 (ru) Способ профилактики и лечения атеросклероза в эксперименте

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee